Andrew Berens
Stock Analyst at Leerink Partners
(1.79)
# 1,882
Out of 4,479 analysts
112
Total ratings
46.6%
Success rate
-8.58%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $110.36 | -12.11% | 17 | May 6, 2024 | |
| NUVL Nuvalent | Upgrades: Outperform | $69 → $110 | $73.00 | +50.68% | 1 | Apr 1, 2024 | |
| INCY Incyte | Upgrades: Outperform | $78 | $59.02 | +32.16% | 12 | Dec 13, 2023 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $10 → $5 | $0.49 | +920.41% | 4 | Aug 15, 2023 | |
| ELEV Elevation Oncology | Upgrades: Outperform | $5 → $8 | $2.80 | +185.71% | 4 | May 30, 2023 | |
| MRUS Merus | Maintains: Outperform | $35 → $48 | $53.09 | -9.59% | 5 | Apr 17, 2023 | |
| BGNE BeiGene | Maintains: Outperform | $236 → $300 | $143.93 | +108.43% | 9 | Jan 20, 2023 | |
| ZYME Zymeworks | Maintains: Market Perform | $8 → $10 | $8.40 | +19.05% | 9 | Jan 20, 2023 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $8.24 | +142.72% | 4 | Jan 5, 2023 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $37 → $28 | $18.93 | +47.91% | 3 | Dec 13, 2022 | |
| ARVN Arvinas | Maintains: Outperform | $74 → $70 | $24.85 | +181.69% | 5 | Nov 23, 2022 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $76.99 | +2.61% | 10 | Nov 14, 2022 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Outperform | $42 → $27 | $3.57 | +656.30% | 7 | Nov 10, 2022 | |
| HOOK HOOKIPA Pharma | Maintains: Outperform | $4 → $3 | $0.58 | +415.82% | 3 | Aug 11, 2022 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $33 → $37 | $42.05 | -12.01% | 8 | Aug 5, 2022 | |
| CGEM Cullinan Oncology | Maintains: Outperform | $36 → $25 | $16.31 | +53.28% | 3 | May 13, 2022 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $9 → $11 | $0.88 | +1,150.00% | 2 | May 5, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $7.15 | - | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | n/a | $4.52 | - | 1 | Oct 14, 2021 | |
| GLUE Monte Rosa Therapeutics | Initiates: Market Perform | n/a | $3.59 | - | 1 | Oct 14, 2021 | |
| TNGX Tango Therapeutics | Initiates: Outperform | n/a | $8.11 | - | 1 | Sep 20, 2021 | |
| OCUL Ocular Therapeutix | Maintains: Equal-Weight | n/a | $6.68 | - | 2 | Jul 14, 2017 |
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $110.36
Upside: -12.11%
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $73.00
Upside: +50.68%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $59.02
Upside: +32.16%
Viracta Therapeutics
Aug 15, 2023
Maintains: Outperform
Price Target: $10 → $5
Current: $0.49
Upside: +920.41%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5 → $8
Current: $2.80
Upside: +185.71%
Merus
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $53.09
Upside: -9.59%
BeiGene
Jan 20, 2023
Maintains: Outperform
Price Target: $236 → $300
Current: $143.93
Upside: +108.43%
Zymeworks
Jan 20, 2023
Maintains: Market Perform
Price Target: $8 → $10
Current: $8.40
Upside: +19.05%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $8.24
Upside: +142.72%
Nurix Therapeutics
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $18.93
Upside: +47.91%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $24.85
Upside: +181.69%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $76.99
Upside: +2.61%
Zentalis Pharmaceuticals
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $3.57
Upside: +656.30%
HOOKIPA Pharma
Aug 11, 2022
Maintains: Outperform
Price Target: $4 → $3
Current: $0.58
Upside: +415.82%
Agios Pharmaceuticals
Aug 5, 2022
Maintains: Outperform
Price Target: $33 → $37
Current: $42.05
Upside: -12.01%
Cullinan Oncology
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $16.31
Upside: +53.28%
Compass Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $0.88
Upside: +1,150.00%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.15
Upside: -
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.52
Upside: -
Monte Rosa Therapeutics
Oct 14, 2021
Initiates: Market Perform
Price Target: n/a
Current: $3.59
Upside: -
Tango Therapeutics
Sep 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.11
Upside: -
Ocular Therapeutix
Jul 14, 2017
Maintains: Equal-Weight
Price Target: n/a
Current: $6.68
Upside: -